Brief: Epo Decision To Grant European Patent For Rencofilstat Further Strengthens Hepion’s Patent Portfolio
02/03/2023 14:23
March 2 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* EPO DECISION TO GRANT EUROPEAN PATENT FOR RENCOFILSTAT
FURTHER
STRENGTHENS HEPION’S PATENT PORTFOLIO
* RENCOFILSTAT'S EXCLUSIVITY MAY EXTEND INTO 2048
* PATENT COVERS 38 EUROPEAN COUNTRIES
Source text for Eikon: ID:nGNX9Vlf1d
Further company coverage: HEPA.O
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement